High plasma TIMP-1 and serum CEA levels during combination chemotherapy for metastatic colorectal cancer are significantly associated with poor outcome

Oncology

Volumn 79, Issue 1-2, 2010, Pages 144-149

  Aldulaymi, Bahir ^c   Byström, Per ^a   Berglund, Åke ^b   Christensen, Ib J ^d   Brünner, Nils ^e   Nielsen, Hans J ^f   Glimelius, Bengt ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c HILLERØD HOSPITAL   (Denmark)

^d FINSEN LABORATORY   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Biomarker; CEA; Colorectal cancer; Metastasis; Prognosis; Response; TIMP 1

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; IRINOTECAN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; ENZYME BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SWEDEN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78649780632     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320686     Document Type: Article

References (32)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P: Estimates of the cancer incidence and mortality in europe in 2006. Ann Oncol 2007; 18: 581-592.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66.
3. Benson AB 3rd: Epidemiology, disease progression, and economic burden of colorectal cancer. J Manag Care Pharm 2007; 13:S5-S18.
4. Chau I, Cunningham D: Treatment in advanced colorectal cancer: what, when and how? Br J Cancer 2009; 100: 1704-1719.
5. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih Ie M, Sibley P, Soletormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP: National academy of clinical biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008; 54:e11-e79.
6. Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH, Punt CJ: A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur J Cancer 2009; 45: 1935-1949.
7. Saif MW, Shah M: K-ras mutations in colorectal cancer: a practice changing discovery. Clin Adv Hematol Oncol 2009; 7: 45- 53, 64.
8. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
9. Sorensen NM, Bystrom P, Christensen IJ, Berglund A, Nielsen HJ, Brunner N, Glimelius B: TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res 2007; 13: 4117-4122.
10. Davidsen ML, Wurtz SO, Romer MU, Sorensen NM, Johansen SK, Christensen IJ, Larsen JK, Offenberg H, Brunner N, Lademann U: Timp-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 2006; 95: 1114-1120.
11. Schrohl AS, Meijer-van Gelder ME, Holten- Andersen MN, Christensen IJ, Look MP, Mouridsen HT, Brunner N, Foekens JA: Primary tumor levels of tissue inhibitor of metalloproteinases- 1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res 2006; 12: 7054-7058.
12. Lipton A, Ali SM, Leitzel K, Demers L, Evans DB, Hamer P, Brown-Shimer S, Pierce K, Carney W: Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer. Cancer 2007; 109: 1933-1939.
13. Willemoe GL, Hertel PB, Bartels A, Jensen MB, Balslev E, Rasmussen BB, Mouridsen H, Ejlertsen B, Brunner N: Lack of timp-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n = 647) with primary breast cancer: A Danish Breast Cancer Cooperative Group study. Eur J Cancer 2009; 45: 2528-2536.
14. Johansen JS, Brasso K, Iversen P, Teisner B, Garnero P, Price PA, Christensen IJ: Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival. Clin Cancer Res 2007; 13: 3244-3249.
15. Glimelius B, Hoffman K, Einarsson R, Pahlman L, Graf W: Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements. Acta Oncol 1996; 35: 141-148.
16. Aldulaymi B, Christensen IJ, Soletormos G, Jess P, Nielsen SE, Brunner N, Nielsen HJ: Changes in soluble cea and timp-1 levels during adjuvant chemotherapy for stage iii colon cancer. Anticancer Res 2010; 30: 233-237.
17. Glimelius B, Sorbye H, Balteskard L, Bystrom P, Pfeiffer P, Tveit K, Heikkila R, Keldsen N, Albertsson M, Starkhammar H, Garmo H, Berglund A: A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (lV5FU2) in patients with metastatic colorectal cancer. Ann Oncol 2008; 19: 909-914.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
19. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer- Hansen G, Brunner N, Stephens RW: Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999; 80: 495-503.
20. Frederiksen C, Lomholt AF, Davis GJ, Dowell BL, Blankenstein MA, Christensen IJ, Brunner N, Nielsen HJ: Changes in plasma TIMP-1 levels after resection for primary colorectal cancer. Anticancer Res 2009; 29: 75-81.
21. Frederiksen CB, Lomholt AF, Lottenburger T, Davis GJ, Dowell BL, Blankenstein MA, Christensen IJ, Brunner N, Nielsen HJ: Assessment of the biological variation of plasma tissue inhibitor of metalloproteinases-1. Int J Biol Markers 2008; 23: 42-47.
22. Lomholt AF, Frederiksen CB, Christensen IJ, Brunner N, Nielsen HJ: Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations. Clin Chim Acta 2007; 380: 128-132.
23. Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, Brunner N: High preoperative plasma tissue inhibitor of metalloproteinase- 1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000; 6: 4292-4299.
24. Holten-Andersen M, Christensen IJ, Nilbert M, Bendahl PO, Nielsen HJ, Brunner N, Fernebro E: Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer patient survival: a validation study. Eur J Cancer 2004; 40: 64-72.
25. Waas ET, Hendriks T, Lomme RM, Wobbes T: Plasma levels of matrix metalloproteinase- 2 and tissue inhibitor of metalloproteinase- 1 correlate with disease stage and survival in colorectal cancer patients. Dis Colon Rectum 2005; 48: 700-710.
26. Holten-Andersen MN, Nielsen HJ, Sorensen S, Jensen V, Brunner N, Christensen IJ: Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. Eur J Cancer 2006; 42: 1889-1896.
27. Wang JY, Lu CY, Chu KS, Ma CJ, Wu DC, Tsai HL, Yu FJ, Hsieh JS: Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res 2007; 39: 245-250.
28. Luparello C, Avanzato G, Carella C, Pucci- Minafra I: Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat 1999; 54: 235-244.
29. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K: Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells: a possible new growth factor in serum. FEBS Lett 1992; 298: 29-32.
30. Liu H, Chen B, Lilly B: Fibroblasts potentiate blood vessel formation partially through secreted factor TIMP-1. Angiogenesis 2008; 11: 223-234.
31. Moller Sorensen N, Vejgaard Sorensen I, Ornbjerg Wurtz S, Schrohl AS, Dowell B, Davis G, Jarle Christensen I, Nielsen HJ, Brunner N: Biology and potential clinical implications of tissue inhibitor of metalloproteinases- 1 in colorectal cancer treatment. Scand J Gastroenterol 2008; 43: 774-786.
32. Frederiksen C, Qvortrup C, Christensen IJ, Glimelius B, Berglund Å, Jensen BV, Nielsen SE, Keldsen N, Nielsen HJ, Brünner N, Pfeiffer P: Plasma TIMP-1 levels and treatment outcome in patients treated with xelox for metastatic colorectal cancer. Ann Oncol 2010, in press.